Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179238 | 0.97 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CALDH1A1NPC1 | |
| SCHEMBL13501653 | 0.80 | CDK5 (0.40) | ADRA2AADRA2BADRA2CALDH1A1NPC1 | |
| SCHEMBL11967236 | 0.77 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CALDH1A1NPC1 | |
| SCHEMBL3290699 | 0.77 | RXFP1 (0.44) | ADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL8006934 | 0.77 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CALDH1A1NPC1 | |
| SCHEMBL22993619 | 0.76 | MAOA (0.35) | ADRA2AADRA2BADRA2C | |
| SCHEMBL11954962 | 0.76 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CNPC1KDM4E | |
| SCHEMBL24253554 | 0.75 | HRH3 (0.36) | — | |
| SCHEMBL24253309 | 0.75 | HRH3 (0.35) | — | |
| SCHEMBL23349384 | 0.75 | CDK5 (0.43) | ADRA2AADRA2BADRA2CALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572353-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20220204473-A1 | COMPOUND AS IRAK INHIBITOR | WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-20210221808-A1 | 3-OXAZOLINONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-07-22 | — | — | US | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-20210046069-A1 | PENTAFLUOROSULFANYL-SUBSTITUTED AMIDE DERIVATIVES, PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-08-04 | — | — | US | disclosed |
| US-10710981-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| US-20200131148-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-10-10 | — | — | US | disclosed |
| US-20190210997-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210997-A1 | ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | FGFR1, FGFR4, FGFR3 | ADRA2A 4111/4885ADRA2B 3470/4885ADRA2C 3469/4885 |
| US-11572353-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | FGFR1, FGFR4, FGFR3 | ADRA2A 4111/4885ADRA2B 3470/4885ADRA2C 3469/4885 |
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | JAK3, ERBB3, CDK3 | ADRA2A 2695/4885ADRA2B 2383/4885ADRA2C 1888/4885 |
| US-10710981-B2 | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | FGFR1, FGFR4, FGFR3 | ADRA2A 4111/4885ADRA2B 3470/4885ADRA2C 3469/4885 |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | IDO1, IDO2, INMT | ADRA2A 3293/4885ADRA2B 2709/4885ADRA2C 2501/4885 |
| US-20210221808-A1 | 3-OXAZOLINONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | IDO1, IDO2, INMT | ADRA2A 2799/4885ADRA2B 2593/4885ADRA2C 1619/4885 |
| US-20210046069-A1 | PENTAFLUOROSULFANYL-SUBSTITUTED AMIDE DERIVATIVES, PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | IDO1, IDO2, KYNU | ADRA2A 1973/4885ADRA2B 2024/4885ADRA2C 1848/4885 |
| US-20220204473-A1 | COMPOUND AS IRAK INHIBITOR | IRAK1, IRAK3, IRAK2 | ADRA2A 4163/4885ADRA2B 3274/4885ADRA2C 4132/4885 |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | JAK3, ERBB3, CDK3 | ADRA2A 2695/4885ADRA2B 2383/4885ADRA2C 1888/4885 |
| US-20200131148-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | RORC, RORB, RORA | ADRA2A 2046/4885ADRA2B 1438/4885ADRA2C 1249/4885 |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | IDO1, IDO2, INMT | ADRA2A 3293/4885ADRA2B 2709/4885ADRA2C 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.